Company Overview
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Why Investors Should Care
Revenue has grown at a 10.0% CAGR over the past five years.
Operating margin of 25.2% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.14.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Jun 2025 Revenue of $1.22B (+5.2% YoY); net profit $73.40M.
- Trailing 12 Months Year-on-year growth — revenue -1.5%, earnings +128.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 10.0%, profit CAGR -2.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 10.04% |
| 1 Year: | -1.50% |
Compounded Profit Growth
| 5 Years: | -2.23% |
| 1 Year: | 128.60% |
Stock Price Performance
| 1 Year: | +36.19% |
| 6 Months: | +8.76% |
| 3 Months: | +24.04% |
| 1 Month: | +31.86% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)75.87 · Overbought
P/E of 101.76 is above the sector median of 25.41 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 10.0% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 101.8.
- Earnings shrank at -2.2% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 76 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TECH Bio-Techne Corporation SPX | 71.23 | 101.76 | $11.15B | 0.59% | 4.29% | 5.34% | 10.04% | -2.23% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 144.61M | 154.15M | 163.97M | - | 162.97M | 174.51M | 184.86M | - | 183.24M | 184.93M | 194.68M | - | 204.20M | 224.25M | 243.55M | 257.72M | 269.28M | 290.38M | 269.65M | 271.58M | 294.15M | 276.94M | 272.60M | 303.43M | 289.46M | 297.03M | 316.18M | 286.56M | 295.88M | 311.42M |
| Gross Profit | 75.74M | 79.38M | 75.39M | 81.59M | 89.99M | - | 87.34M | 88.14M | 96.68M | - | 97.87M | 101.83M | 110.26M | - | 107.60M | 113.02M | 124.61M | - | 118.41M | 121.40M | 130.06M | - | 137.73M | 150.90M | 168.27M | 171.00M | 183.69M | 201.46M | 179.59M | 183.36M | 202.16M | 185.19M | 176.59M | 204.60M | 183.02M | 193.89M | 214.56M | 188.11M | 191.28M | 208.29M |
| Operating Income | 34.58M | 39.43M | 31.03M | 36.02M | 43.53M | - | 29.16M | 17.88M | 33.50M | - | 26.03M | 24.15M | 43.08M | - | 25.76M | 33.60M | 44.09M | - | 33.33M | 36.99M | 47.79M | - | 49.09M | 50.99M | 68.63M | 63.22M | 62.35M | 90.45M | 56.32M | 67.89M | 80.21M | 55.86M | 38.00M | 67.00M | 39.99M | 47.42M | 38.71M | 47.66M | 54.46M | 75.50M |
| Net Income | 33.21M | 24.29M | 22.71M | 25.85M | 30.29M | 25.63M | 18.84M | 7.47M | 22.17M | 27.61M | 15.86M | 48.85M | 19.74M | 41.70M | 17.40M | 17.56M | 44.65M | 16.46M | 14.40M | 119.62M | 36.43M | 58.85M | 33.40M | 46.27M | 45.78M | 69.61M | 80.17M | 60.74M | 89.56M | 50.01M | 70.22M | 50.99M | 27.46M | 49.06M | 33.60M | 34.89M | 22.59M | 38.19M | 38.01M | 51.05M |
| Diluted EPS | 0.89 | 0.65 | 0.61 | 0.69 | 0.81 | 0.69 | 0.50 | 0.20 | 0.59 | 0.74 | 0.42 | 1.29 | 0.52 | 1.07 | 0.45 | 0.45 | 1.15 | 0.42 | 0.37 | 3.02 | 0.92 | 1.48 | 0.83 | 1.15 | 1.12 | 1.69 | 0.49 | 0.37 | 0.55 | 0.31 | 0.43 | 0.31 | 0.17 | 0.31 | 0.21 | 0.22 | 0.14 | 0.24 | 0.24 | 0.32 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 263.96M | 269.05M | 289.96M | 314.56M | 310.57M | 357.76M | 452.25M | 499.02M | 563.00M | 642.99M | 714.01M | 738.69M | 931.03M | 1.11B | 1.14B | 1.16B | 1.22B |
| Gross Profit | 208.03M | 214.15M | 224.94M | 235.80M | 231.11M | 251.41M | 307.28M | 336.66M | 374.54M | 432.14M | 473.49M | 483.19M | 632.85M | 756.50M | 769.82M | 769.73M | 790.27M |
| Operating Income | 150.78M | 156.33M | 163.06M | 166.21M | 158.47K | 159.75M | 147.02M | 150.59M | 120.58M | 136.18M | 146.72M | 157.42M | 237.30M | 296.59M | 298.94M | 206.69M | 102.25M |
| Net Income | 105.24M | 109.78M | 112.30M | 112.33M | 112.56M | 110.95M | 107.73M | 104.48M | 76.09M | 126.15M | 96.07M | 229.30M | 140.41M | 272.05M | 285.26M | 168.10M | 73.40M |
| Diluted EPS | 2.78 | 2.94 | 3.02 | 3.04 | 3.05 | 3.00 | 2.89 | 2.80 | 2.03 | 3.31 | 2.47 | 5.82 | 0.87 | 1.66 | 1.76 | 1.05 | 0.46 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2008 | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 472.00M | 518.82M | 617.67M | 719.32M | 778.10M | 862.49M | 1.06B | 1.13B | 1.56B | 1.59B | 1.88B | 2.03B | 2.26B | 2.29B | 2.64B | 2.70B | 2.56B |
| Total Equity | 487.13M | 456.48M | 501.79M | 586.12M | 674.44M | 737.54M | 795.26M | 846.93M | 879.28M | 949.63M | 1.08B | 1.17B | 1.38B | 1.56B | 1.70B | 1.97B | 2.07B | 1.92B |
| Cash & Equivalents | 166.99M | 160.94M | 94.14M | 77.61M | 116.67M | 163.79M | 318.57M | 54.53M | 64.24M | 91.61M | 121.99M | 100.89M | 146.62M | 199.09M | 172.57M | 180.57M | 151.79M | 162.19M |
| Current Liabilities | - | - | 17.02M | 18.19M | 35.75M | 32.08M | 26.39M | 39.77M | 54.15M | 135.52M | 79.51M | 101.98M | 106.67M | 152.28M | 176.02M | 128.51M | 159.38M | 175.85M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 111.32M | 111.26M | 127.19M | 126.75M | 123.56M | - | - | 144.16M | 143.72M | 170.37M | 181.62M | 205.22M | 352.16M | 325.27M | 254.39M | 298.98M | 287.56M |
| Investing Cash Flow | 21.28M | -114.61M | -114.19M | -21.67M | -31.20M | - | - | -107.57M | -305.95M | -38.71M | -336.80M | 27.09M | -243.52M | -96.85M | -265.65M | -203.03M | -35.18M |
| Financing Cash Flow | -119.44M | -50.51M | -36.29M | -64.62M | -44.68M | - | - | -23.37M | 189.11M | -99.19M | 134.38M | -183.80M | -62.55M | -242.85M | 22.62M | -122.40M | -253.91M |
| Capital Expenditure | -6.56M | -4.64M | -3.63M | -6.02M | -22.45M | -13.82M | -19.91M | -16.90M | -15.18M | -20.93M | -25.41M | -51.74M | -44.30M | -44.91M | -38.24M | -62.88M | -31.01M |
| Free Cash Flow | 104.77M | 106.62M | 123.56M | 120.73M | 101.11M | - | - | 127.26M | 128.54M | 149.43M | 156.21M | 153.47M | 307.86M | 280.36M | 216.15M | 236.10M | 256.55M |
| Share Buybacks | 90.63M | 14.97M | 1.94M | 23.60M | 1.82M | 0 | 0 | - | - | 0 | 15.40M | 50.11M | 43.18M | 160.95M | 19.56M | 80.04M | 275.73M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 78.8% | 79.6% | 77.6% | 75.0% | 74.4% | 70.3% | 67.9% | 67.5% | 66.5% | 67.2% | 66.3% | 65.4% | 68.0% | 68.4% | 67.7% | 66.4% | 64.8% |
| Operating Margin % | 57.1% | 58.1% | 56.2% | 52.8% | 0.1% | 44.7% | 32.5% | 30.2% | 21.4% | 21.2% | 20.5% | 21.3% | 25.5% | 26.8% | 26.3% | 17.8% | 8.4% |
| Net Margin % | 39.9% | 40.8% | 38.7% | 35.7% | 36.2% | 31.0% | 23.8% | 20.9% | 13.5% | 19.6% | 13.5% | 31.0% | 15.1% | 24.6% | 25.1% | 14.5% | 6.0% |
| ROE % | 23.1% | 21.9% | 19.2% | 16.7% | 15.3% | 14.0% | 12.7% | 11.9% | 8.0% | 11.7% | 8.2% | 16.6% | 9.0% | 16.0% | 14.5% | 8.1% | 3.8% |
| ROCE % | - | 31.2% | 27.2% | 24.3% | 0.0% | 19.1% | 14.4% | 14.0% | 8.5% | 9.0% | 8.2% | 8.2% | 11.2% | 14.0% | 11.9% | 8.1% | 4.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.83% | 12.26M | $868.63M |
| 2 | Vanguard Capital Management LLC | 6.50% | 10.18M | $720.98M |
| 3 | Morgan Stanley | 5.45% | 8.53M | $604.34M |
| 4 | FMR, LLC | 5.05% | 7.90M | $559.51M |
| 5 | Vanguard Portfolio Management LLC | 4.14% | 6.48M | $458.97M |
| 6 | State Street Corporation | 3.75% | 5.87M | $415.63M |
| 7 | Wellington Management Group, LLP | 3.27% | 5.12M | $362.64M |
| 8 | Geode Capital Management, LLC | 3.27% | 5.11M | $362.09M |
| 9 | Maverick Capital Ltd. | 3.03% | 4.74M | $335.69M |
| 10 | Invesco Ltd. | 2.93% | 4.59M | $325.00M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TECH
What IBM’s Bad Quarter Means for Tech Stocks - Barron's
<a href="https://news.google.com/rss/articles/CBMickFVX3lxTFAzb2FmVWROVklxTl9MT1hnd3pjRG9NRVQ0ZWlmNnhBbFhPTzRrSjF5clBqdjI1OXBqLVhGaFZSZ0FBcWtIMEh4SkNEV3UxNkM0N0hRa0ctQmg4cFd0Y2JhX3NjYW5BdklBSlBkYVFhZDRSZw?oc=5" target="_blank">What IBM’s Ba…
Cathie Wood buys $22.8 million of surging tech stock - thestreet.com
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQcVppaTNXM011Sm1Tc3hrME1JaU9LV1VDeGV1WEdLSWYteTdBc3lWQWxwNDhseGVyTnBvVENPaWdMU2d4ZTBvRUhMTmZxVmV6amhacVRBQVhOVndPckx2XzN4SVdXR0owV0c3T21EeHFxQUs4ajkwLWpSWjlpaEdMdjZsVzJ6S3N1M1ZLTV…
SK Hynix South Korean shares jump 11% as Asia tech stocks rally - CNBC
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE9Yb1lWM3daRzFqNjhOU0tqMkZQYmNTUFYtelBSWnkyeEdQVlR1dnI2Yl8wQUtHM1BydklndUsyVnVHMEdZOVRXeGxkMWhISUNDWjN4LVFacDhDT2l6dkZUdS1nZXVBZlVrSDcyZHlSZDh4eXVRUmhELdIBfkFVX3lxTE9vUjFSM0ZsUi1rOE…
Asian Stocks Poised to Track US Gains on Soft CPI: Markets Wrap - Bloomberg.com
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNMVdOYXZybUY1TWlNaEY5cC14SUpCMkRHd0dyYlVkQVN3Q3QzVk1OWFdrakttSTZCTVg3YlhMa211NXdMRmM0aXRleG91MEwyQlpMaFRUODZleFh2WF9ua1hGa0dmTDZ6T0xWaFRfYV9DbXAwamNkbHpwR1J6enRmcC1JLUZrYWdCVkNadV…
Markets News, July 13, 2026: Major Indexes End Lower as Chip Stocks Drop; Oil Prices Soar as Trump Says US Reinstating Strait of Hormuz Blockade - Investopedia
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxOM21JT2JGZnpGNUphcDJrbnBhemN0OThxUWt4WnZDazh5MVNpeHREX0VVUktPWFRSZlZuR1hrOWVXMDlzWXo0ZUFkNU93X2FMaENJYUJKNklmTWxITEpuYnl0aDBxX3NhV3lkUWZaTzYzLUV1eVlTM2dMWWVJYXRtT2VsYWM0Mm9YdXVQc1…
Buy These 4 Tech Stocks That Are Still Cheap Despite 100%+ YTD Rally - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPTmJkcDVlbTg2V2hoRkVKcU9Ubnl5R040S3BtVzhfU2g2MUNzaW5PMHJJU29TLUxJT1pudFcxelk5SmdienVkakprRlVNejdCVkxURlRQdzdpdzlEZVEwR1Q0ZkhFdWtnSzF6YW9VU0JiemcxeFVRS3pLa1NQNHd4R2wxX3doQl96bzBOcX…
TECH — Frequently Asked Questions
What is the current share price of Bio-Techne Corporation (TECH)?
As of 2026-07-14 21:23 PDT, Bio-Techne Corporation (TECH) trades at $71.23 on NasdaqGS. Its 52-week range is $43.22 to $71.36.
What is the market capitalisation of TECH?
Bio-Techne Corporation (TECH) has a market capitalisation of $11.15B on NasdaqGS.
What is the P/E ratio of TECH?
TECH trades at a trailing price-to-earnings (P/E) ratio of 101.76. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 4.19.
Does TECH pay a dividend?
Bio-Techne Corporation (TECH) currently offers a dividend yield of 0.59%.
What is the return on equity (ROE) of TECH?
TECH has a return on equity (ROE) of 5.34%. Its return on capital employed (ROCE) is 4.29%.
Is TECH a good stock to buy?
This page provides a data-driven analysis of Bio-Techne Corporation (TECH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.